Vice President, DMPK

Overview

Job Summary

C4 Therapeutics (C4T) is seeking an accomplished and visionary Vice President of Drug Metabolism & Pharmacokinetics (DMPK) to lead the strategic, scientific, and operational direction of our DMPK organization. As a core member of the scientific leadership team, you will architect and execute an end to end DMPK strategy purpose built for targeted protein degraders—from early discovery through IND enabling studies and into early clinical development.

You will shape a next generation DMPK framework driven by clinical learnings from C4T’s degrader programs, advances in PK/PD modeling, and the unique translational challenges of beyond rule of 5 molecules. This highly visible role will partner closely across Chemistry, Biology, Pharmacology, CMC, and Clinical Pharmacology to accelerate degrader design, optimize dose and exposure predictions, and ensure data driven decision making across the portfolio.

We are ambitious in our mission and seek a leader who will elevate the DMPK function to best in industry standards.

• Establish and communicate a compelling DMPK vision tailored to targeted protein degraders, informed by C4T’s clinical, translational, and discovery insights.
• Define portfolio‑wide DMPK strategy spanning discovery, candidate selection, IND‑enabling pharmacokinetics, and Phase 1 clinical translation.
• Champion innovation in mechanistic and translational PK/PD approaches to advance degrader program success.
• Serve as a senior advisor to executive leadership on DMPK‑related program risks, decision points, and timelines.

• Oversee all in vitro and in vivo ADME, PK, PK/PD and toxicology activities supporting degrader optimization and program advancement.
• Drive development of predictive PK/PD, human PK, and dose projection models for degrader molecules.
• Direct IND‑enabling DMPK packages, including:
• Cross‑species PK studies
• Metabolism and metabolite identification
• Plasma‑protein binding and distribution studies
• DDI risk assessments (CYP inhibition/induction, transporter studies)
• Bioanalytical method development
• Guide interpretation of clinical PK findings and integration back into discovery and early development strategies.

• Partner deeply with Medicinal Chemistry to guide degrader design based on PK liabilities, exposure drivers, and mechanistic ADME insights.
• Collaborate with Pharmacology and Translational Medicine to establish PK/PD relationships, biomarker integration, and exposure‑response strategies.
• Work with CMC to support formulation, develop ability assessments, and clinical supply readiness.
• Engage Clinical Development and Clinical Pharmacology to define early clinical PK strategies and influence dose‑escalation planning.

• Define, optimize and streamline workflows to fit portfolio needs and budget
• Lead, mentor, and develop team of internal and external scientists (CRO and consultants)
• Build a culture of scientific rigor, innovation, proactive partnership, and operational excellence.
• Manage external CRO relationships to ensure quality, timeliness, and strategic alignment with program goals.
• Oversee departmental budget, resource planning, and vendor strategy.

• Represent C4T in scientific and regulatory interactions as the DMPK subject matter expert.
• Participate in scientific forums, publish impactful research, and maintain awareness of emerging tools and trends in TPD and ADME science.

Required:

• A PhD in Pharmacokinetics, Pharmacology, Pharmaceutical Sciences, Biochemistry, or related field required with at least fifteen years of industry experience in DMPK/ADME/PK, with broad capabilities across pharmacokinetics, pharmacodynamics, ADME, human PK modeling, PK/PD determinations, and clinical pharmacology that demonstrate expert knowledge of pharmacokinetic and drug metabolism principles for small molecule drug development
• Demonstrated experience supporting discovery‑to‑IND and IND‑to‑clinic transitions, including strong translational experience working with products of this nature; understanding what happens in…